Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy…
A representative of the International Association of Fire Fighters appeared before a congressional subcommittee recently to push for a total ban of asbestos in…
Legislation aimed at providing the U.S. Food and Drug Administration with more oversight of the cosmetics industry is one step closer to being implemented.
Asbestos is widely known as an occupational hazard, but emerging evidence suggests that prolonged exposure to environmental asbestos could lead to severe autoimmune…
Health officials are warning Maui residents to exercise caution during cleanup following deadly wildfires as ash and debris may be filled with toxic substances,…
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration. Avenge Bio, a biotechnology company working…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Who Am I Calling?
Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation's most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
